Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RenovaroCube
Amsterdam, Netherlands
- Ownership
- Private
- Development stage
- Other
01
Overview
RenovaroCube's liquid biopsy AI platform demonstrated the ability to detect cancer via cfDNA fragmentomics and methylomics in blood with accuracy comparable to state-of-the-art methods using less data; presented at ESMO Congress 2024. Diagnostic products are commercializing, but therapeutic programs are developed by the parent group's other units
- Therapeutic areas
- OncologyHematology
- Modalities
- Platform (AI-driven diagnostics)Liquid biopsy technologyMulti-omic analysisDeep learning models for fragmentomics, methylomics, and panel biomarker analysis
- Industry
- Molecular Diagnostics
02
Partnerships
Oxford Nanopore (sequencing tech)Nvidia (supercomputing/AI platforms: Parabricks, BioNeMo, Monai, Nemo)
Beyond the preview
Go deeper on RenovaroCube.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RenovaroCube.